ArticleERJ open research2021
Upper airway symptoms associate with the eosinophilic phenotype of COPD.
Article in ERJ open research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Anti-type 2 monoclonal antibody therapy for eosinophilic COPD beyond triple therapy: a systematic review and meta-analysis with strict eosinophil inclusion criteria.Frontiers in medicine · 2026Pooled it
- Beyond Triple Therapy: Anti-Type 2 Biologic Therapies for Eosinophilic COPD and Respiratory Comorbidities - a Review of Clinical Evidence.Current allergy and asthma reports · 2026Review
- The Nose-Lung Axis in Chronic Obstructive Pulmonary Disease: An Emerging Interface for Clinical Endotyping, Biomarker Discovery, and Integrated Management.Diagnostics (Basel, Switzerland) · 2026Article
- Biologics for eosinophilic COPD: current applications and future prospects.Frontiers in immunology · 2026Review
- Type 2 inflammation in chronic obstructive pulmonary disease: A promising treatable trait and practice recommendations.Chinese medical journal pulmonary and critical care medicine · 2025Article
- Oropharyngeal enlargement in obstructive lung disease: quantification and machine learning.ERJ open research · 2025Article
- Eosinophil count and treatment response in COPD patients.Lung India : official organ of Indian Chest Society · 2025Article
- Sinonasal Symptoms in COPD: Burden and Associations with Clinical Markers of Disease.International journal of chronic obstructive pulmonary disease · 2022Article
- Changes in systemic inflammation after pulmonary rehabilitation in patients with COPD and severe physical inactivity - an exploratory study.Chronic respiratory diseaseObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is growing evidence that upper airway symptoms coexist with lower airway symptoms in COPD. Still, the prevalence and impact of upper airway disease on the nature and course of COPD remain unclear. We aimed to describe this in a cross-sectional study.
methodsWe examined a cohort of COPD patients with pulmonary function tests, induced sputum, blood eosinophils, atopy tests and computed tomography (CT) of the paranasal sinuses. Lower airway symptoms were assessed using the COPD Assessment Test (CAT), and upper airway symptoms were assessed using the nasal subdomain of the 22-item Sino Nasal Outcome Test (SNOT22
findingsIn total, 180 patients (female 55%, age 67±8 years, forced expiratory volume in 1 s (FEV
conclusionCOPD patients with upper airway disease showed increased evidence of eosinophilic disease and increased lower airway symptom burden.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.